 Hill-Rom NYSE:HRC had its price objective reduced by Morgan Stanley from 123.00 to 112.00 in a research note released on Monday, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the medical technology companys stock. A number of other research firms also recently issued reports on HRC. Raymond James decreased their target price on ... 